Your browser doesn't support javascript.
loading
Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Clostridioides difficile.
Budi, Noah; Godfrey, Jared J; Safdar, Nasia; Shukla, Sanjay K; Rose, Warren E.
Afiliação
  • Budi N; School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705 nbudi@wisc.edu.
  • Godfrey JJ; Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705.
  • Safdar N; Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705.
  • Shukla SK; Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI.
  • Rose WE; School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705.
Article em En | MEDLINE | ID: mdl-33649111
ABSTRACT
Clostridioides difficile (C. difficile) infections (CDI) are commonly treated with antibiotics that do not impact the dormant spore form of the pathogen. CDI-directed antibiotics, such as vancomycin and metronidazole, can destroy the vegetative form of C. difficile and protective microbiota. After treatment, spores can germinate into vegetative cells causing clinical disease relapse and further spore shedding. This in vitro study compares the combination of germinants with vancomycin or omadacycline to antibiotics alone in eradicating C. difficile spores and vegetative cells. Among the four strains in this study, omadacycline minimum inhibitory concentrations (0.031-0.125 mg/L) were lower than vancomycin (1-4 mg/L). Omadacycline nor vancomycin in media alone reduced spore counts. In three of the four strains, including the epidemic ribotype 027, spore eradication with germinants was 94.8-97.4% with vancomycin and 99.4-99.8% with omadacycline (p<0.005). In ribotype 012, either antibiotic combined with germinants resulted in 100% spore eradication at 24 hours. The addition of germinants with either antibiotic did not result in significant toxin A or B production, which were below the limit of detection (<1.25 ng/mL) by 48 hours. Limiting the number of spores present in patient GI tracts at the end of therapy may be effective at preventing recurrent CDI and limiting spore shedding in the healthcare environment. These results with germinants warrant safety and efficacy evaluations in animal models.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article